Adult T-cell Leukemia/Lymphoma Clinical Trials

25 clinical trials for Adult T-cell Leukemia/Lymphoma across international registries, including 6 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL) — RECRUITING · PHASE1
• A Registry for People With T-cell Lymphoma — RECRUITING
• A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma — RECRUITING · PHASE1
• Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma — RECRUITING · PHASE2
• Two Step Haplo With Radiation Conditioning — RECRUITING · PHASE2
• Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients — RECRUITING · PHASE2
• BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma — COMPLETED · PHASE2
• Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01) — ACTIVE_NOT_RECRUITING · PHASE2
• Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma — SUSPENDED · PHASE1
• Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma — COMPLETED · PHASE2
• A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) — COMPLETED · PHASE2
• Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2
• A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy — COMPLETED · PHASE1
• Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma — COMPLETED · PHASE2
• Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma — COMPLETED · PHASE2
• KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL) — COMPLETED · PHASE2
• Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias — WITHDRAWN · PHASE1
• Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma — WITHDRAWN · PHASE1
• Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL — COMPLETED · PHASE1
• Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma — COMPLETED · NA
• A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma — COMPLETED · PHASE1
• A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma — COMPLETED · PHASE2
• Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15 — COMPLETED · PHASE2
• Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma — COMPLETED · PHASE2
• Lenalidomide in HTLV-1 Adult T-Cell Leukemia — COMPLETED · PHASE2

Refine this search